Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ativan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Lorazepam Tablets 2 mg |
| 2 | ACTIVE_COMPARATOR | Ativan Tablets 2 mg |
| Name | Type | Description |
|---|---|---|
| Lorazepam Tablets 2 mg | DRUG | 2mg, single dose fasting |
| Ativan Tablets 2 mg | DRUG | 2mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administratio...
Ativan is a small molecule drug being studied in healthy volunteers. It is currently in Phase 1 clinical development. The drug is being investigated for use in healthy individuals as part of a clinical trial.
Ativan is developed by Viatris Inc., a company traded on the stock exchange under the ticker VTRS. The company is conducting clinical research on this drug.
Ativan is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The drug is being studied in healthy volunteers.
Ativan has one completed clinical trial, NCT00649818, titled "Fasting Study of Lorazepam Tablets 2 mg and Ativan Tablets 2 mg." This Phase 1 study enrolled 28 healthy participants in the United States and was active-controlled.
Ativan is being studied in a clinical trial that compares it to lorazepam tablets. The trial NCT00649818 is a fasting study of lorazepam tablets 2 mg and Ativan tablets 2 mg, indicating the two are being evaluated together.